Cancer of Unknown Primary Site Clinical Trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum doublet induction chemotherapy.
|Contact||Reference Study ID Number: MX39795 www.roche.com/about_roche/roc|
|Phone||888-662-6728 (U.S. Only)|
|Start date||July 10, 2018|
|Completion date||April 16, 2022|
|Not yet recruiting||